Ardelyx appoints Mark Kaufmann as chief business officer
Role includes business development, licensing and strategic planning
Kaufmann was formerly chief executive of Allostera and Celmed BioSciences.
‘Mark’s deep understanding of the biotechnology business, coupled with his substantial experience at the most senior levels in business development and planning will serve Ardelyx well during our next phase of corporate development,’ said Mike Raab, chairman and ceo of Ardelyx.
Kaufmann has more than 20 years of experience in the biopharmaceutical industry in the US and Canada in business and corporate development roles.
Most recently, he was president and ceo of Allostera Pharma, a venture-backed, preclinical company focused on autoimmune diseases.
Prior to joining Allostera, Kaufmann was president and ceo of Celmed BioSciences, where he was responsible for raising funds and selling the company to Kiadis Pharma, a European biotechnology company. He has also held roles at Nexia Biotechnologies, Conceptis Technologies and MedImmune.
You may also like
Cell & Gene Therapy
BioEcho Life Sciences introduces the EchoLUTION Tissue RNA Kit for fast and reliable RNA extraction without phenol/chloroform
BioEcho Life Sciences announces the launch of the EchoLUTION Tissue RNA Kit, expanding its RNA portfolio, for simplified and efficient RNA extraction from a variety of tissues